Figure 1.

Characterization of anlotinib as a vascular endothelial growth factor receptor‐2 (VEGFR2) inhibitor. A, Chemical structure of anlotinib. B, Molecular modeling of the VEGFR2–anlotinib/sunitinib complex. Hydrogen bonds are presented as yellow dashed lines, and critical residues are presented as maroon sticks. Anlotinib (cyan, docked pose with structure PDB code 4ASD) and sunitinib (orange, from crystallographic structure PDB code 4AGD). C, Molecular modeling of the c‐Kit–anlotinib complex (orange) and VEGFR2–anlotinib complex (cyan). Hydrogen bonds are presented as yellow dashed lines, and critical residues are presented as maroon sticks (VEGFR2) and dark green sticks (c‐Kit)